TheraSphere With Durvalumab and Tremelimumab for HCC
← catalyst calendarNCT05063565 · readout ≤ 314 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →. With Biocompatibles UK Ltd.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
36
Countries
France, Italy, Spain +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-03 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Device: TheraSphere Y-90 glass microsphere therapy
- Drug: Durvalumab (Imfinzi) immunotherapy
- Drug: Tremelimumab immunotherapy
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR)
measured Start of Treatment (Day 1) up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (18 months after the last patient is treated)
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed